This inventor holds 1 USPTO granted patent. Top assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovations of Shaobao Wang
Introduction
Shaobao Wang is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for cancer treatment. His work is characterized by a focus on innovative compounds that target specific biological pathways.
Latest Patents
Wang holds a patent for "Tricyclic derivatives inhibitor, preparation method, and applications thereof." This invention involves an inhibitor containing a tricyclic derivative, a preparation method for the inhibitor, and a pharmaceutical composition that includes the inhibitor. The patent also outlines the use of this compound as a phosphoinositide 3 kinase (PI3K) inhibitor in the treatment of cancer and diseases or conditions that are mediated by or dependent on PI3K imbalance. He has 1 patent to his name.
Career Highlights
Throughout his career, Shaobao Wang has worked with prominent companies in the pharmaceutical industry. He has been associated with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. and Shanghai Hansoh Biomedical Co., Ltd. His experience in these organizations has allowed him to contribute to various innovative projects and advancements in drug development.
Collaborations
Wang has collaborated with several professionals in his field, including Peng Gao and Guangjun Sun. These collaborations have further enhanced his research and development efforts, leading to impactful innovations in pharmaceuticals.
Conclusion
Shaobao Wang's contributions to the field of pharmaceuticals, particularly through his innovative patent, highlight his role as a significant inventor. His work continues to influence the development of treatments for critical health conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile